Non-invasive assessment of liver injury in non-alcoholic fatty liver disease: A review of literature

Current Molecular Medicine

Volumn 16, Issue 8, 2016, Pages 721-737

  Maida, M ^a   Macaluso, F S ^a   Salomone, F ^b   Petta, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Division of Gastroenterology   (Italy)

Author keywords

Liver biopsy; NAFLD; NASH; Non invasive assessment; Steatosis

Indexed keywords

ADIPONECTIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CYTOKERATIN 18; FATTY ACID BINDING PROTEIN 4; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESISTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INSULIN BLOOD LEVEL; LIPID ACCUMULATION PRODUCT INDEX; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MULTICENTER STUDY (TOPIC); NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RECEIVER OPERATING CHARACTERISTIC; REVIEW; TRANSIENT ELASTOGRAPHY; ALGORITHM; ANIMAL; BIOPSY; CLINICAL DECISION MAKING; FIBROSIS; LIVER; META ANALYSIS; METABOLISM; MORBIDITY; MORTALITY; MULTIMODAL IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROGNOSIS;

ALGORITHMS; ANIMALS; APOPTOSIS; BIOMARKERS; BIOPSY; CLINICAL DECISION-MAKING; FIBROSIS; HUMANS; LIVER; MORBIDITY; MORTALITY; MULTIMODAL IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 84995957648     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524016666161004143613     Document Type: Review

References (151)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-90
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85
3. Adams LA, Lymp JF, St Sauver J, et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21
4. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol 2015; 62: S47-64
5. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: S152-60
6. Rousselet MC, Michalak S, Dupre F, et al. Hepatitis Network 49. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-64
7. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57
8. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-64
9. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-40
10. Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23
11. Zelber-Sagi S, Salomone F, Yeshua H, et al. Non-highdensity lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int 2014; 34: e128-35
12. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in non-alcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8
13. Chalasani N, Younossi Z, Lavine JE, et al. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012: 142: 1592-609
14. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292: 13-5
15. Debongnie JC, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut 1981; 22: 130-5
16. Foster KJ, Dewbury KC, Griffith AH, Wright R. The accuracy of ultrasound in the detection of fatty infiltration of the liver. Br J Radiol 1980; 53: 440-2
17. Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol 2000; 35: 319-24
18. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90
19. Macaluso FS, Maida M, Camma C, et al. Body mass index and liver stiffness affect accuracy of ultrasonography in detecting steatosis in patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2014; 12: 878-884.e1
20. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 2007; 189: W320-3
21. Pamilo M, Sotaniemi EA, Suramo I, Lahde S, Arranto AJ. Evaluation of liver steatotic and fibrous content by computerized tomography and ultrasound. Scand J Gastroenterol 1983; 18: 743-7
22. Mendler MH, Bouillet P, Le Sidaner A, et al. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and singleenergy CT, with special reference to iron overload. J Hepatol 1998; 28: 785-94
23. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994; 12: 487-95
24. Cowin GJ, Jonsson JR, Bauer JD, et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008; 28: 937-45
25. Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a metaanalysis. Eur Radiol 2011; 21: 87-97
26. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36: 1825-35
27. Friedrich-Rust M, Romen D, Vermehren J, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-31
28. Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a non-invasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902-10
29. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911-8
30. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for non-invasive assessment of steatosis using Fibroscan: validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-53
31. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33
32. Kim JH, Kwon SY, Lee SW, Lee CH. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver Int 2011; 31: 1600-1
33. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137: 865-72
34. Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol 2010; 10: 98
35. Park YJ, Lim JH, Kwon ER, et al. Development and validation of a simple index system to predict non-alcoholic fatty liver disease. Korean J Hepatol 2011; 17: 19-26
36. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting non-alcoholic fatty liver disease. Dig Liver Dis 2010; 42: 503-8
37. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10
38. Gastaldelli A, Kozakova M, Hojlund K, et al. RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-44
39. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcohol steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34
40. Lassailly G, Caiazzo R, Hollebecque A, et al. Validation of non-invasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011; 23: 499-506
41. Poynard T, Lassailly G, Diaz E, et al; FLIP consortium. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One 2012; 7: e30325
42. Hyysalo J, Mannisto VT, Zhou Y, et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2014; 60: 839-46
43. Miele L, Forgione A, La Torre G, et al. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of non-alcoholic steatohepatitis in a pilot cohort of subjects with non-alcoholic fatty liver disease. Transl Res 2009; 154: 194-201
44. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing non-alcoholic steatohepatitis from simple steatosis in patients with non-alcoholic fatty liver disease. Liver Int 2006; 26: 151-6
45. Sumida Y, Yoneda M, Hyogo H, et al. Japan Study Group of Non-alcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in non-alcoholic fatty liver disease. J Gastroenterol 2011; 46: 257-68
46. Dixon JB, Bhathal PS, O’Brien PE. Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100
47. Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting non-alcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916-23
48. Panasiuk A, Dzieciol J, Panasiuk B, Prokopowicz D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 6198-202
49. Tarantino G, Conca P, Coppola A, Vecchione R, Di Minno G. Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis. Eur J Clin Invest 2007; 37: 48-53
50. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in non-alcoholic fatty liver disease. Hepatology 2006; 44: 27-33
51. Diab DL, Yerian L, Schauer P, et al. Cytokeratin 18 fragment levels as a non-invasive biomarker for non-alcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 2008; 6: 1249-54
52. Yilmaz Y, Dolar E, Ulukaya E, et al. Solubile forms of extracellular cytokeratin 18 may differentiate simple steatosis from non-alcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-44
53. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarker for non-alcoholic steatohepatitis: A multicenter validation study. Hepatology 2009; 50: 1072-8
54. Musso G, Gambino R, Cassader M, Pagano G. Metaanalysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-49
55. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related non-alcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-7
56. Shen J, Chan HL, Wong GL, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012; 56: 1363-70
57. Anty R, Iannelli A, Patouraux S, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32: 1315-22
58. Tamimi TI, Elgouhari HM, Alkhouri N, et al. An apoptosis panel for non-alcoholic steatohepatitis diagnosis. J Hepatol 2011; 54: 1224-9
59. Joka D, Wahl K, Moeller S, et al. Prospective biopsycontrolled evaluation of cell death biomarkers for prediction of liver fibrosis and non-alcoholic steatohepatitis. Hepatology 2012; 55: 455-64
60. Iijima H, Moriyasu F, Tsuchiya K, et al. Decrease in accumulation of ultrasound contrast microbubbles in nonalcoholic steatohepatitis. Hepatol Res 2007; 37: 722-30
61. Sevastianova K, Hakkarainen A, Kotronen A, et al. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Radiology 2010; 256: 466-73
62. Zardi EM, De Sio I, Ghittoni G, et al. Which clinical and sonographic parameters may be useful to discriminate NASH from steatosis? J Clin Gastroenterol 2011; 45: 59-63
63. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56
64. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-9
65. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of non-invasive markers of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12
66. Musso G, Cassader M, Gambino R. Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for liver histology and cardiovascular risk in NAFLD. Hepatology 2012; 56: 788-9
67. Adams LA, George J, Bugianesi E, et al. Complex noninvasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26: 1536-43
68. Sumida Y, Yoneda M, Hyogo H, et al. Japan Study Group of Non-alcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese non-alcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2
69. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54
70. Wong VW, Wong GL, Chim AM, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008; 103: 1682-8
71. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009; 58: 1566-7
72. Qureshi K, Clements RH, Abrams GA. The utility of the ‘NAFLD fibrosis score’ in morbidly obese subjects with NAFLD. Obes Surg 2008; 18: 264-70
73. Harrison SA, Oliver D, Arnold HL, Gogia S, NeuschwanderTetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-7
74. Ruffillo G, Fassio E, Alvarez E, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 160-3
75. Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, et al. Validation of the BARD scoring system in Polish patients with non-alcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010; 10: 67
76. Cales P, Laine F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-73
77. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the non-invasive evaluation of liver fibrosis. Ann Hepatol 2008; 7: 350-7
78. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62
79. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratori and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-24
80. Cales P, Boursier J, Chaigneau J, et al. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 2010; 30: 1346-54
81. Tahan V, Canbakan B, Balci H, et al. Serum gammaglutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 2008; 55: 1433-8
82. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-9
83. Bugianesi E, Manzini P, D’Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepatology 2004; 39: 179-87
84. Manousou P, Kalambokis G, Grillo F, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011; 31: 730-9
85. Angulo P, George J, Day CP, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 1163-9
86. Amato MC, Giordano C, Galia M, et al. AlkaMeSy Study Group. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33: 920-2
87. Vongsuvanh R, George J, McLeod D, van der Poorten D. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 2012; 57: 392-8
88. Petta S, Amato MC, Di Marco V, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 238-47
89. Ratziu V, Massard J, Charlotte F, et al. LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6
90. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40
91. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13
92. Guha IN, Parkes J, Roderick P, et al. Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60
93. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Non-alcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399-408
94. Joka D, Wahl K, Moeller S, et al. Prospective biopsycontrolled evaluation of cell death biomarkers for prediction of liver fibrosis and non-alcoholic steatohepatitis. Hepatology 2012; 55: 455-64
95. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50
96. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8
97. Ganne-Carrie N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44: 1511-7
98. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73
99. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-9
100. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-4
101. Sagir A, Erhardt A, Schmitt M, Haüssinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47: 592-7
102. Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57: 1288-93
103. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a metaanalysis. Gastroenterology 2008; 134: 960-74
104. Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric non-alcoholic steatohepatitis. Hepatology 2008; 48: 442-8
105. Yoneda M, Mawatari H, Fujita K, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with non-alcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371-8
106. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62
107. Ziol M, Kettaneh A, Ganne-Carrie N, Barget N, TengherBarna I, Beaugrand M. Relationships between fibrosis amounts assessed by morphometry and liver stiffness measurements in chronic hepatitis or steatohepatitis. Eur J Gastroenterol Hepatol 2009; 21: 1261-8
108. Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71
109. Lupsor M, Badea R, Stefanescu H, et al. Performance of unidimensional transient elastography in staging nonalcoholic steatohepatitis. J Gastrointestin Liver Dis 2010; 19: 53-60
110. Petta S, Di Marco V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-60
111. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208
112. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol 2012; 56: 564-70
113. de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScanR. J Hepatol 2012; 56: 833-9
114. Petta S, Craxi A. Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe? Hepatology 2012; 55: 1309; author reply 1309-10
115. Petta S, Maida M, Macaluso FS, et al. The severity of steatosis influences liver stiffness measurement in patients with non-alcoholic fatty liver disease. Hepatology 2015; 62: 1101-10
116. Palmeri ML, Wang MH, Dahl JJ, Frinkley KD, Nightingale KR. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol 2008; 34: 546-58
117. Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int 2010; 30: 538-45
118. Friedrich-Rust M, Wunder K, Kriener S, et al. Liver fibrosis in viral hepatitis: non-invasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252: 595-604
119. Haque M, Robinson C, Owen D, Yoshida EM, Harris A. Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: a pilot study. Ann Hepatol 2010; 9: 289-93
120. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new non-invasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13
121. Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2011; 106: 2112-20
122. Yoneda M, Suzuki K, Kato S, et al. Non-alcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-7
123. Palmeri ML, Wang MH, Rouze NC, et al. Non-invasive evaluation of hepatic fibrosis using acoustic radiation forcebased shear stiffness in patients with non-alcoholic fatty liver disease. J Hepatol 2011; 55: 666-72
124. Friedrich-Rust M, Romen D, Vermehren J, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-31
125. Sevastianova K, Hakkarainen A, Kotronen A, et al. Nonalcoholic fatty liver disease: detection of elevated nicotinamide adenine dinucleotide phosphate with in vivo 3.0-T 31P MR spectroscopy with proton decoupling. Radiology 2010; 256: 466-73
126. Cui J, Ang B, Haufe W, et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 2015; 41: 1271-80
127. Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60: 1920-8
128. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-20
129. Younossi Z, Stepanova M, Rafiq N, et al. Pathologic criteria for non-alcoholic steatohepatitis (NASH): interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1873-81
130. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9
131. Kleiner DE, Brunt EM, Van Natta M, et al. for Non-alcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005; 41: 1313-21
132. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74
133. Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the non-invasive diagnostic accuracy for severe liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2015; 35: 1566-73
134. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of non-alcoholic fatty liver disease. Hepatology 2011; 53: 1883-94
135. Petta S, Grimaudo S, Camma C, et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with nonalcoholic fatty liver disease. J Hepatol 2012; 56: 1356-62
136. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008; 51: 1947-53
137. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-74
138. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-9
139. Bhala N, Angulo P, van der Poorten D, et al. The natural history of non-alcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-16
140. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51
141. Vergniol J, Foucher J, Terrebonne E, et al. Non-invasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9
142. Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012; 55: 1406-15
143. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F. Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 2010; 10: 56
144. Handberg A, Hojlund K, Gastaldelli A, et al. Plasma sCD36 associates with markers of atherosclerosis, insulin resistance, and fatty liver in a healthy population. J Intern Med 2012; 271: 294-304
145. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of non-alcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18: 237-43
146. Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 2004; 145: 1842-8
147. Villa E, Karampatou A, Camma C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140: 776-9
148. Villa E, Vukotic R, Camma C, et al. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS One 2012; 7: e44624
149. Abdelmalek MF, Suzuki A, Guy C, et al. Non-alcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with non-alcoholic fatty liver disease. Hepatology 2010; 51: 1961-71
150. Cheung O, Kapoor A, Puri P, et al. The impact of fat distribution on the severity of non-alcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46: 1091-100
151. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-24.